Skip to content

Study · Animal study (in vivo) · horse · 2019

1 result

Evaluation of a Proprietary Slow-Release Oxytocin Formulation on Corpus Luteum Function in Mares.

Sarnecky BA, Vanderwall DK, Mason HM, Kirschner SM, Ambrose B, Parker TL

Journal of equine veterinary science29 Jan 2019Cited by 1 (Europe PMC)

PMID31133312 (opens in a new tab)DOI10.1016/j.jevs.2019.01.004 (opens in a new tab)PepBankPUB-31133312
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mares, two injections of slow-release oxytocin prolonged corpus luteum function in 6 of 8 mares (75%) versus 0 of 8 (0%) controls (P < .01).

    In plain wordsIn mares, two slow-release oxytocin injections prolonged corpus luteum function in 6 of 8 mares, compared with none of the untreated mares.

    Peptide
    Oxytocin
    Outcome
    IncreaseProlonged corpus luteum function
    Study

    horsen = 16

    mares
    Comparator
    Untreated control
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2,400 IU oxytocin as SR-OT, 1.0 mL · intramuscular · two injections, day 7 and day 10 after ovulationAs given in this study (horse).

    Measurements

    prolonged CL function
    75%
    SR-OT mares
    prolonged CL function
    0%
    control mares

    Source sentences

    Summary
    Corpus luteum function was prolonged in 0/8 (0%) control mares and 6/8 (75%) of the SR-OT-treated mares (P < .01).
    1 context sentence
    Summary · context
    Mares were examined via transrectal palpation and ultrasonography to determine the day of ovulation (day 0) and then randomly assigned to a nontreated control group and an SR-OT treatment group (n = 8 mares/group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.